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Bleeding Avoidance in
Transcatheter Aortic Valve
Replacement
A Call to ACTion?*
Matthew I. Tomey, MD,y Roxana Mehran, MDyz
New York, New York
Bleeding complications after transcatheter aortic valve
replacement (TAVR) are common. Reported rates of major
bleeding at 30 days include 9.3% and 16.8% in the high- and
extreme-risk cohorts of the PARTNER (Placement of
Aortic Transcatheter Valve) trial (1,2), 24.1% in the
extreme-risk cohort of the CoreValve U.S. Pivotal Trial (3),
and 7.2% to 9.7% in large international registries (4). Major
or life-threatening bleeding events, as classiﬁed by the Valve
Academic Research Consortium (5), are potent predictors of
mortality (6–9). To the extent that anticoagulation used
during TAVR may inﬂuence periprocedural bleeding risk,
there is a need to identify best anticoagulation strategies to
minimize clinically important bleeding while maintaining
antithrombotic efﬁcacy.See page 140A joint expert consensus document published in March
2012 favors use of anticoagulation during TAVR to maintain
an activated clotting time (ACT) of>300 s (10), but the basis
for this target and means to achieve it are ill-deﬁned. In this
issue of JACC: Cardiovascular Interventions, Bernelli et al.
(11) contribute important new observations from a compar-
ison of 2 strategies for initial unfractionated heparin dosing
during TAVR on the basis of weight or baseline ACT.
The investigators conceived an ACT-based dosing
strategy after noticing that ACT was often elevated in*Editorials published in JACC: Cardiovascular Interventions reﬂect the views of
the authors and do not necessarily represent the views of JACC: Cardiovascular
Interventions or the American College of Cardiology.
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administration of 5,000, 4,000 or 3,000 U of unfractio-
nated heparin for ACT <140 s, 140 to 175 s, or 175 s,
respectively. Over a span of 5 years, this ACT-based
dosing strategy was used with roughly equal frequency
(n ¼ 174) in comparison with a conventional dosing
strategy of 80 units of unfractionated heparin per kilogram
of actual body weight (n ¼ 188). In all patients, after initial
dosing, unfractionated heparin was titrated in an unspec-
iﬁed manner to achieve an ACT of 200 to 300 s. For the
present analysis, the investigators retrospectively compared
patients at a single center selected for each strategy with
respect to a primary outcome measure of 30-day major
bleeding.
Consistent with reported outcomes, major bleeding was
common at 30 days (21.0%), mostly procedure-related
(82.4%), and associated with increased mortality. Differ-
ences in bleeding between the 2 treatment groups were
striking, with a nearly 4.5-fold higher incidence of major
bleeding among patients treated with a weight-based dosing
strategy (33.5% vs. 7.5%, p < 0.001), as well as a signiﬁ-
cantly higher rate of life-threatening bleeding (20.2% vs.
12.1%, p ¼ 0.04). Upon multivariable adjustment, use of an
ACT-based dosing strategy was associated with better than
6:1 odds of freedom from 30-day major bleeding.
Although these differences in bleeding are dramatic, these
ﬁndings must be interpreted with caution. Retrospective
analysis is ﬂawed for the purpose of comparing strategies,
even with propensity adjustment as the investigators did.
Despite a nonparsimonious model incorporating 42 separate
variables, likelihood of residual confounding remains. In
particular, it is notable that of the 4 operators at this single
center, 2 preferred 1 dosing strategy and 2 preferred the
other. Although choice of strategy was “fairly balanced,” as
the investigators note, it is difﬁcult to separate the choice of
strategy here from the choice of operator. Given the
importance of technical skill and experience in optimizing
vascular access and closure in TAVR, operator differences in
this relatively small sample may have exerted signiﬁcant
impact on bleeding outcomes. Indeed, in a separate analysis
of the data excluding the earliest 59 patients to account for a
learning curve, differences in life-threatening bleeding were
attenuated.
Second, this study calls into question the appropriate use
of ACT for anticoagulation monitoring in the particular
setting of TAVR. With current practice derived largely
empirically from the PARTNER trial and extrapolation
from percutaneous coronary intervention (4), we may inad-
equately account for hemostatic differences between patients
with coronary disease and patients with severe aortic
stenosis.
Perhaps the most interesting observation of this study is
the one that inspired it: the elevated baseline ACT in
patients with severe aortic stenosis (159.1 s, compared with
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153136.1 in contemporary control subjects with coronary artery
disease). ACT is a point-of-care test that measures the
time necessary for whole blood to clot upon introduction
of an activator of the intrinsic coagulation cascade, such as
celite, kaolin, or glass beads (12). Although useful for
measuring the effects of high-dose heparin or the direct
thrombin inhibitor bivalirudin, ACT may also be inﬂu-
enced by abnormalities of platelet count or function. This
is highly pertinent in severe aortic stenosis, in which high
molecular weight multimers of von Willebrand factor may
fragment across the calciﬁc aortic valve. When combined
with submucosal angiodysplasias and tendency to gastro-
intestinal bleeding, this acquired deﬁciency of von Wille-
brand factor forms the basis for what is known as Heyde
syndrome (13). Variable accompanying deﬁciency of factor
VIII, which binds von Willebrand factor in plasma, im-
pairs the intrinsic coagulation cascade, with potential
impact on both the effects of heparin and the ACT (14).
Whatever the means of determining dosing, it is likely
that lower total doses of heparin contributed to observed
differences in bleeding events. Patients in the ACT-guided
dosing group received 33% less heparin overall (4,000 vs.
6,000 U, p < 0.001). It has been hypothesized, and the
investigators discuss, that the advanced age, frailty, and
comorbidities common to patients undergoing TAVR may
alter the pharmacokinetics and pharmacodynamics of hep-
arin such that lower doses are needed to achieve the desired
antithrombotic effect.
Whereas it is plausible that reduced heparin dosing may
reduce periprocedural bleeding events, the determination of
whether this constitutes a best strategy for anticoagulation
awaits the results of a large, prospective randomized trial
designed to evaluate not only bleeding endpoints but also
carefully adjudicated thrombotic endpoints including stroke.
In this study, there were 5 strokes (1.4%) and 4 transient
ischemic attacks (1.1%), ﬁgures that are low in comparison
with results of the PARTNER (4.7%) (2) and CoreValve
trials (3.9%) (3) and reported registries outside of Italy (1.9%
to 5.0%) (4).
Above all, this study underscores the opportunity to
improve bleeding avoidance during TAVR. Beyond heparin,
additional options for anticoagulation are on the horizon with
potential to reduce periprocedural bleeding, including biva-
lirudin, now well established as a bleeding-avoidance strategy
during percutaneous coronary intervention (15). We look
forward to the results of the ongoing BRAVO 2/3 (Effect of
Bivalirudin on Aortic Valve Intervention Outcomes 2/3)
randomized trial of bivalirudin versus unfractionated hep-
arin in patients undergoing transfemoral TAVR (16).Reprint requests and correspondence: Dr. Roxana Mehran, The
Zena andMichael A.Wiener Cardiovascular Institute, Mount Sinai
School of Medicine, One Gustave L. Levy Place, Box 1030, New
York, New York 10029. E-mail: roxana.mehran@mountsinai.org.REFERENCES
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